The overall goal for the Core is to facilitate the translation of results from basic mechanistic studies which are a component of each of the SCoR Projects into a greater understanding of the pathophysiology of human heart failure syndromes. Basic investigations at the molecular, cellular or organ level are complemented by the ability to identify in a well characterized human heart failure population genetic defects in or abnormal expression of candidate hypertrophy transducer or effector molecules targeted for study in this SCOR. A focus of the Clinical Core is the four year old Cincinnati Heart Failure Study, a longitudinal study of heart failure patients in the University of Cincinnati Heart Failure and Transplantation Program wherein clinical characteristics, genotypic analysis, physiological studies, and information on clinical course are acquired, archived analyzed and made available to the SCOR Project Leaders. Accordingly, the relevant objectives of the Core for Individual Projects are: 1) To screen, recruit, and perform the clinical characterization of early (NYHA Class I or II) and late (NYHA Class III or IV) heart failure patients for genetic analysis; 2) To perform invasive and non-invasive hemodynamic analysis of subjects with defined genetic betaAR or PLB polymorphisms; 3) To acquire, store, and distribute cardiac tissue from explanted failing hearts at cardiac transplantation and harvested non-failing hearts not used for transplantation; 4) To acquire epicardial patch biopsies from explanted failing or non-failing hearts of patients undergoing coronary artery bypass procedures. The Core thus not only provides access at multiple levels to a local population of Heart Failure Patients, but also acts as a consultative service in the design of appropriate hypothesis-testing studies within the patient population or on individual patients, in a manner which maximizes scientific return without compromising patient care.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL052318-06
Application #
6317578
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (O1))
Project Start
2000-02-14
Project End
2005-01-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
$244,100
Indirect Cost
Name
University of Cincinnati
Department
Type
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Shaikh, Sana A; Sahoo, Sanjaya K; Periasamy, Muthu (2016) Phospholamban and sarcolipin: Are they functionally redundant or distinct regulators of the Sarco(Endo)Plasmic Reticulum Calcium ATPase? J Mol Cell Cardiol 91:81-91
Kwong, Jennifer Q; Molkentin, Jeffery D (2015) Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab 21:206-214
Karch, Jason; Molkentin, Jeffery D (2015) Regulated necrotic cell death: the passive aggressive side of Bax and Bak. Circ Res 116:1800-9
Liu, Ruijie; Correll, Robert N; Davis, Jennifer et al. (2015) Cardiac-specific deletion of protein phosphatase 1? promotes increased myofilament protein phosphorylation and contractile alterations. J Mol Cell Cardiol 87:204-13
Correll, Robert N; Eder, Petra; Burr, Adam R et al. (2014) Overexpression of the Na+/K+ ATPase ?2 but not ?1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 114:249-256
van Berlo, Jop H; Kanisicak, Onur; Maillet, Marjorie et al. (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337-41
Molkentin, Jeffery D (2013) Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells. Circ Res 113:16-9
Maurya, Santosh K; Periasamy, Muthu; Bal, Naresh C (2013) High gender -specific susceptibility to curare- a neuromuscular blocking agent. Biol Res 46:75-8
Davis, Jennifer; Maillet, Marjorie; Miano, Joseph M et al. (2012) Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ Res 111:761-77
Wu, Xu; Eder, Petra; Chang, Baojun et al. (2010) TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci U S A 107:7000-5

Showing the most recent 10 out of 193 publications